In several clinical trials, the SLAMF7 monoclonal antibody elotuzumab has shown a great advantage in combination with other therapies for the treatment of relapsed or refractory multiple myeloma (RRMM) (63-65). This evidence concerns the gene SLAMF7 and AL amyloidosis.